Search

Your search keyword '"Kirby, Joslyn S"' showing total 400 results
Start Over Author "Kirby, Joslyn S"
400 results on '"Kirby, Joslyn S"'

1. Wound drainage measurements: a narrative review

Author

Shih, Terri, Park, Sarah, Thorlacius, Linnea R., Daveluy, Steven, Garg, Amit, Goegji, Susanne D., Kirby, Joslyn S., McGrath, Barry M., Riis, Peter T., Villumsen, Bente, Zalik, Kari, Jemec, Gregor B. E., and Hsiao, Jennifer L.

Published
2023
Full Text
View/download PDF

3. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations

Author

Garg, Amit, Malviya, Neeta, Strunk, Andrew, Wright, Shari, Alavi, Afsaneh, Alhusayen, Raed, Alikhan, Ali, Daveluy, Steven D, Delorme, Isabelle, Goldfarb, Noah, Gulliver, Wayne, Hamzavi, Iltefat, Jaleel, Tarannum, Kimball, Alexa B, Kirby, Joslyn S, Kirchhof, Mark G, Lester, Janice, Lev-Tov, Hadar, Lowes, Michelle A, Micheletti, Robert, Orenstein, Lauren A, Piguet, Vincent, Sayed, Christopher, Tan, Jerry, and Naik, Haley B

Subjects
Clinical Research, Health Services, Obesity, Prevention, Digestive Diseases, Aetiology, 2.1 Biological and endogenous factors, Cardiovascular, Good Health and Well Being, Canada, Comorbidity, Female, Hidradenitis Suppurativa, Humans, Metabolic Syndrome, Pyoderma Gangrenosum, acne, cardiovascular disease, comorbidity, Crohn's disease, depression, dermatologist, diabetes mellitus, dissecting cellulitis of the scalp, down syndrome, dyslipidemia, generalized anxiety disorder, guidelines, herpes zoster, hidradenitis suppurativa, hypertension, inflammatory bowel disease, lymphoma, metabolic syndrome, North America, obesity, pilonidal disease, polycystic ovary syndrome, pyoderma gangrenosum, screening, sexual dysfunction, smoking, spondyloarthritis, substance use, suicide, systemic, ulcerative colitis, Clinical Sciences, Dermatology & Venereal Diseases
Abstract

BackgroundHidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk.ObjectiveTo provide evidence-based screening recommendations for comorbidities linked to HS.MethodsSystematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population. The screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence, and magnitude of association, as well as benefits, harms, and feasibility of screening. The level of evidence and strength of corresponding screening recommendation were graded by using the Strength of Recommendation Taxonomy (SORT) criteria.ResultsScreening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovary syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis, and sexual dysfunction. It is also recommended to screen patients with Down syndrome for HS. The decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity.LimitationsScreening recommendations represent one component of a comprehensive care strategy.ConclusionsDermatologists should support screening efforts to identify comorbid conditions in HS.

Published
2022

4. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Author

Kimball, Alexa B, Jemec, Gregor B E, Sayed, Christopher J, Kirby, Joslyn S, Prens, Errol, Ingram, John R, Garg, Amit, Gottlieb, Alice B, Szepietowski, Jacek C, Bechara, Falk G, Giamarellos-Bourboulis, Evangelos J, Fujita, Hideki, Rolleri, Robert, Joshi, Paulatsya, Dokhe, Pratiksha, Muller, Edward, Peterson, Luke, Madden, Cynthia, Bari, Muhammad, and Zouboulis, Christos C

Published
2024
Full Text
View/download PDF

9. Discrepancies in hidradenitis suppurativa lesion characterization by providers and patients

Author

Greenlund, Lindsey, primary, Herzog, Claire, additional, Wendland, Zachary, additional, Rypka, Katelyn, additional, Frew, John W., additional, Kirby, Joslyn S., additional, Alavi, Afsaneh, additional, Khalid, Bisma, additional, Lowes, Michelle A., additional, Garg, Amit, additional, Marzano, Angelo V., additional, Zouboulis, Christos C., additional, Tzellos, Thrasyvoulos, additional, Jaleel, Tarannum, additional, and Goldfarb, Noah, additional

Published
2024
Full Text
View/download PDF

10. Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II

Author

Ingram, John R., primary, Porter, Martina, additional, Chovatiya, Raj, additional, Giamarellos-Bourboulis, Evangelos J., additional, Bechara, Falk G., additional, Fujita, Hideki, additional, Gulliver, Wayne, additional, Muller, Edward, additional, Bari, Muhammad, additional, Rolleri, Robert, additional, Byerly, Rob, additional, and Kirby, Joslyn S, additional

Published
2024
Full Text
View/download PDF

12. Contributors

Author

Alavi, Afsaneh, primary, Aleshin, Maria, additional, Bechara, Falk G., additional, Bennett, Richard G., additional, Birnbaum, Ron, additional, Brownstone, Nicholas, additional, Buechler, Connor R., additional, Shree' Byrd, Angel, additional, Charrow, Alexandra P., additional, Cole, Emily F., additional, Collier, Erin K., additional, Daveluy, Steven D., additional, Fernandez, Jennifer M., additional, Frew, John W., additional, Garg, Amit, additional, George, Ralph, additional, Goldberg, Stephanie R., additional, Goldfarb, Noah, additional, Guilbault, Sandra, additional, Hamzavi, Iltefat H., additional, Hazen, Paul G., additional, Henderson, Marsha, additional, Hendricks, Aleksi J., additional, Hsiao, Jennifer L., additional, Jaleel, Tarannum, additional, Johnson, Lydia J., additional, Join-Lambert, Olivier, additional, Kerns, Michelle L., additional, Kimball, Alexa B., additional, Kirby, Joslyn S., additional, Kohli, Indermeet, additional, Lenczowski, Joi, additional, Lev-Tov, Hadar, additional, Liao, Wilson, additional, Lowes, Michelle A., additional, Lyons, Alexis B., additional, Malviya, Neeta, additional, Micheletti, Robert G., additional, Morss-Walton, Peyton C., additional, Myers, Bridget, additional, Naik, Haley B., additional, Narla, Shanthi, additional, Nassif, Aude, additional, Nguyen, Tien Viet, additional, Nikolakis, Georgios, additional, O'Brien, Elizabeth, additional, Orenstein, Lauren A.V., additional, Parks-Miller, Angie, additional, Patel, Zarine S., additional, Porter, Martina L., additional, Price, Kyla N., additional, Ramesh, Mayur, additional, Resnik, Barry I., additional, Santillan, Monica Rosales, additional, Sachdeva, Muskaan, additional, Sanchez, Daniela P., additional, Savage, Kevin T., additional, Sayed, Chris, additional, Shah, Monica, additional, Shaver, Rob Leland, additional, Shi, Vivian Y., additional, Smogorzewski, Jan M., additional, Succaria, Farah, additional, Svoboda, Ryan M., additional, Thompson, Alyssa M., additional, Vaiopoulos, Aristeidis G., additional, Veerabagu, Surya A., additional, Walsh, Joseph R., additional, Weigelt, Maximillian A., additional, Wortsman, Ximena, additional, and Zouboulis, Christos C., additional

Published
2022
Full Text
View/download PDF

13. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II):two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Author

Kimball, Alexa B., Jemec, Gregor B.E., Sayed, Christopher J., Kirby, Joslyn S., Prens, Errol, Ingram, John R., Garg, Amit, Gottlieb, Alice B., Szepietowski, Jacek C., Bechara, Falk G., Giamarellos-Bourboulis, Evangelos J., Fujita, Hideki, Rolleri, Robert, Joshi, Paulatsya, Dokhe, Pratiksha, Muller, Edward, Peterson, Luke, Madden, Cynthia, Bari, Muhammad, Zouboulis, Christos C., Kimball, Alexa B., Jemec, Gregor B.E., Sayed, Christopher J., Kirby, Joslyn S., Prens, Errol, Ingram, John R., Garg, Amit, Gottlieb, Alice B., Szepietowski, Jacek C., Bechara, Falk G., Giamarellos-Bourboulis, Evangelos J., Fujita, Hideki, Rolleri, Robert, Joshi, Paulatsya, Dokhe, Pratiksha, Muller, Edward, Peterson, Luke, Madden, Cynthia, Bari, Muhammad, and Zouboulis, Christos C.

Abstract

Background Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. Methods BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Patients aged 18 years or older with moderate-to-severe hidradenitis suppurativa were randomly assigned 2:2:2:1 using interactive response technology (stratified by worst Hurley Stage at baseline and baseline systemic antibiotic use) to receive subcutaneous bimekizumab 320 mg every 2 weeks; bimekizumab 320 mg every 2 weeks to week 16, then every 4 weeks to week 48; bimekizumab 320 mg every 4 weeks to week 48; or placebo to week 16, then bimekizumab 320 mg every 2 weeks. The primary outcome was an hidradenitis suppurativa clinical response of at least 50%, defined as a reduction in total abscess and inflammatory nodule count of at least 50% from baseline with no increase from baseline in abscess or draining tunnel count (HiSCR50) at week 16. Efficacy analyses included all randomly assigned study patients (intention-to-treat population). Safety analyses included all patients who received at least one full or partial dose of study treatment in the safety set, and of bimekizumab in the active-medication set. These trials are registered at ClinicalTrials.gov, NCT04242446 and NCT04242498, and both are completed. Findings Patients for BE HEARD I were recruited from Feb 19, 2020, to Oct 27, 2021, and 505 patients were enrolled and randomly assigned. Patients for BE HEARD II were recruited from March 2, 2020, to July 28, 2021, and 509 patients were enrolled and randomly assigned. The primary outcome at week 16 was met in the group who received bimekizumab every 2 weeks using modified non, Background: Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. Methods: BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Patients aged 18 years or older with moderate-to-severe hidradenitis suppurativa were randomly assigned 2:2:2:1 using interactive response technology (stratified by worst Hurley Stage at baseline and baseline systemic antibiotic use) to receive subcutaneous bimekizumab 320 mg every 2 weeks; bimekizumab 320 mg every 2 weeks to week 16, then every 4 weeks to week 48; bimekizumab 320 mg every 4 weeks to week 48; or placebo to week 16, then bimekizumab 320 mg every 2 weeks. The primary outcome was an hidradenitis suppurativa clinical response of at least 50%, defined as a reduction in total abscess and inflammatory nodule count of at least 50% from baseline with no increase from baseline in abscess or draining tunnel count (HiSCR50) at week 16. Efficacy analyses included all randomly assigned study patients (intention-to-treat population). Safety analyses included all patients who received at least one full or partial dose of study treatment in the safety set, and of bimekizumab in the active-medication set. These trials are registered at ClinicalTrials.gov, NCT04242446 and NCT04242498, and both are completed. Findings: Patients for BE HEARD I were recruited from Feb 19, 2020, to Oct 27, 2021, and 505 patients were enrolled and randomly assigned. Patients for BE HEARD II were recruited from March 2, 2020, to July 28, 2021, and 509 patients were enrolled and randomly assigned. The primary outcome at week 16 was met in the group who received bimekizumab every 2 weeks using modified non-responder imputation; hi

Published
2024

14. Inpatient Management of Hidradenitis Suppurativa: A Delphi Consensus Study.

Author

Needham, McKenzie, Pichardo, Rita, Alavi, Afsaneh, Chang, Aileen Y., Daveluy, Steven, DeNiro, Katherine L., Dewan, Anna, Eshaq, Milad, Fox, Lindy, Hsiao, Jennifer Lin, Kaffenberger, Benjamin Harris, Kirby, Joslyn S., Kroshinsky, Daniela, Ortega-Loayza, Alex G., Manusco, Jennifer Brescoll, Micheletti, Robert G., Mostaghimi, Arash, Nelson, Caroline A., Pasieka, Helena B., and Porter, Martina L.

Subjects
HIDRADENITIS suppurativa, DELPHI method, INPATIENT care, PATIENT care, DERMATOLOGISTS, HOSPITAL care
Abstract

Inpatient hospitalization of individuals with hidradenitis suppurativa (HS) has increased. Inpatient services may not be familiar enough with this disease to understand how to manage severe HS and/or HS flares. It would be beneficial to the inpatient medical community to establish consensus recommendations on holistic inpatient care of patients with HS. A survey study was developed and distributed by Wake Forest University School of Medicine (Winston-Salem, North Carolina). A total of 26 dermatologists participated in the Delphi process, and the process was conducted in 2 rounds. Participants voted on proposal statements using a 9-point scale (1=very inappropriate; 9=very appropriate). Statements were developed using current published guidelines for management of HS and supportive care guidelines for other severe inpatient dermatologic diseases. A total of 50 statements were reviewed and voted on between the 2 rounds. Consensus was determined using the RAND/UCLA Appropriateness Method. Twenty-six dermatologists completed the first-round survey, and 24 completed the second-round survey. The 40 consensus recommendations generated through these surveys can serve as a resource for providers caring for inpatients with HS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice

Author

Mastacouris, Nicole, primary, Tannenbaum, Rachel, additional, Strunk, Andrew, additional, Koptyev, Jonathan, additional, Aarts, Pim, additional, Alhusayen, Raed, additional, Bechara, Falk G., additional, Benhadou, Farida, additional, Bettoli, Vincenzo, additional, Brassard, Alain, additional, Brown, Debra, additional, Choon, Siew Eng, additional, Coutts, Patricia, additional, da Silva, Dimitri Luz Felipe, additional, Daveluy, Steven, additional, Dellavalle, Robert P., additional, del Marmol, Veronique, additional, Emtestam, Lennart, additional, Gebauer, Kurt, additional, George, Ralph, additional, Giamarellos-Bourboulis, Evangelos J., additional, Goldfarb, Noah, additional, Hamzavi, Iltefat, additional, Hazen, Paul G., additional, Horváth, Barbara, additional, Hsiao, Jennifer, additional, Ingram, John R., additional, Jemec, Gregor B. E., additional, Kirby, Joslyn S., additional, Lowes, Michelle A., additional, Marzano, Angelo V., additional, Matusiak, Lukasz, additional, Naik, Haley B., additional, Okun, Martin M., additional, Oon, Hazel H., additional, Orenstein, Lauren A. V., additional, Paek, So Yeon, additional, Pascual, José C., additional, Fernandez-Peñas, Pablo, additional, Resnik, Barry I., additional, Sayed, Christopher J., additional, Thorlacius, Linnea, additional, van der Zee, Hessel H., additional, van Straalen, Kelsey R., additional, and Garg, Amit, additional

Published
2023
Full Text
View/download PDF

17. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire

Author

Ingram, John R., Ciaravino, Valerie, Rolleri, Robert, Pansar, Ingrid, Dias-Barbosa, Carla, and Kirby, Joslyn S.

Subjects
HIDRADENITIS suppurativa, TEST validity, QUALITY of life, DIARY (Literary form), COGNITIVE interviewing
Abstract

Background: Hidradenitis suppurativa (HS), a chronic skin condition that causes pain and physical dysfunction, can impact significantly on quality of life. Disease-specific tools have been designed to assess the impact of HS on patients, including the HS Symptom Daily Diary (HSSDD), the HS Symptom Questionnaire (HSSQ), and the HS Quality of Life (HiSQOL©) questionnaire, which have been developed into electronic instruments (eHSSDD, eHSSQ, and eHiSQOL©). Objectives: The objective of this study was to establish the content validity of the electronic version of the HSSDD and HSSQ, and the acceptability and usability of the HSSDD, HSSQ, and HiSQOL©, using concept elicitation and cognitive debriefing interviews. Methods: This was a non-interventional qualitative video interview study involving participants aged ≥18 years with moderate to severe HS recruited from a single clinical site in the USA. Interviews gathered feedback on participants' symptom experience, followed by training and completion of the eHSSDD, eHSSQ, and eHiSQOL© questionnaires on electronic handheld devices. Participants were then interviewed on the content of the eHSSDD and eHSSQ and the acceptability and usability of all three instruments. Interviews were transcribed and qualitatively analysed. Results: Twenty participants with moderate to severe HS (median age: 41.5 [range: 20.0–64.0]; n = 16/20 female) were included. All participants found the eHSSDD, eHSSQ, and eHiSQOL© instructions clear and described the instruments as "easy", "simple" and "self-explanatory". Overall understanding of individual items within the eHSSDD and eHSSQ was high; however, 6/20 participants had difficulty in understanding the average skin pain item in the eHSSDD. All participants were able to accurately recall their symptoms within the recall periods of the eHSSDD and eHSSQ, although 4/20 participants found the 24-h recall period of the eHSSDD limiting. Completion time was quick across all instruments, and usability was high, with the majority of participants reporting no difficulty in completing questionnaires on electronic devices. Conclusion: The concepts covered in the eHSSDD and eHSSQ are relevant and important to patients, supporting their content validity. The findings also provide evidence of acceptability and usability of the eHSSDD, eHSSQ, and eHiSQOL©. A limitation was that all participants were recruited from a single site, which may have introduced selection bias and thus limited the generalisability of results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project

Author

Garg, Amit, primary, Rawal, Sahil, additional, Akilov, Oleg, additional, Alavi, Afsaneh, additional, Ardon, Christine, additional, Bechara, Falk G, additional, Cohen, Arnon D, additional, Cohen, Steven R, additional, Daveluy, Steven, additional, del Marmol, Véronique, additional, Delage, Maïa, additional, Esmann, Solveig, additional, Fisher, Shani, additional, Giamarellos-Bourboulis, Evangelos J, additional, Glowaczewska, Amelia, additional, Goldfarb, Noah, additional, Gonzalez Brant, Elena, additional, Grimstad, Øystein, additional, Guilbault, Sandra, additional, Hamzavi, Iltefat, additional, Hughes, Rosalind, additional, Ingram, John R, additional, Jemec, Gregor B E, additional, Ju, Qiang, additional, Kappe, Naomi, additional, Kirby, Brian, additional, Kirby, Joslyn S, additional, Lowes, Michelle A, additional, Matusiak, Lukasz, additional, Micha, Stella, additional, Micheletti, Robert G, additional, Miller, Angela P, additional, Moseng, Dagfinn, additional, Naik, Haley B, additional, Nassif, Aude, additional, Nikolakis, Georgios, additional, Paek, So Yeon, additional, Pascual, Jose Carlos, additional, Prens, Errol, additional, Resnik, Barry, additional, Riad, Hassan, additional, Sayed, Christopher, additional, Smith, Saxon D, additional, Soliman, Yssra, additional, Szepietowski, Jacek C, additional, Tan, Jerry, additional, Thorlacius, Linnea, additional, Tzellos, Thrasyvoulos, additional, van der Zee, Hessel H, additional, Villumsen, Bente, additional, Wang, Lanqi, additional, Zouboulis, Christos C, additional, and Strunk, Andrew, additional

Published
2023
Full Text
View/download PDF

23. List of Contributors

Author

Abdullah, Anthony, primary, Abrouk, Michael, additional, Ahad, Tashmeeta, additional, Ahmed, Imtiaz, additional, Al Hammadi, Anwar, additional, Allen, Caroline, additional, Almohssen, Amer Ali, additional, Alwan, Wisam, additional, Ameen, Mahreen, additional, Amini, Sadegh, additional, Anderson, Bryan E., additional, Anhalt, Grant J., additional, Baker, Donald J., additional, Bala, Harini Rajgopal, additional, Baltz, Julia, additional, Banach, David, additional, Banfield, Cedric C., additional, Baran, Robert, additional, Bardhan, Ajoy, additional, Barkham, Melissa C., additional, Bello, Ysabel M., additional, Benton, Emma, additional, Bergfeld, Wilma F., additional, Berkowitz, Eric, additional, Berman, Brian, additional, Bernhard, Jeffrey D., additional, Bernstein, Daniel, additional, Berth-Jones, John, additional, Bhate, Chinmoy, additional, Bhatia, Bhavnit K., additional, Blume, Jonathan E., additional, Bordet, Nevianna, additional, Borysiewicz, Catherine, additional, Brauner, Gary J., additional, Brodell, Robert T., additional, Brown, Marc D., additional, Burd, Robert M., additional, Burdick, Anne E., additional, Butala, Niraj, additional, Callen, Jeffrey P., additional, Camacho, Ivan D., additional, Camasmie, Helena, additional, Caplivski, Daniel, additional, Cappell, Mitchell S., additional, Casey, Genevieve A., additional, Chan, Lawrence S., additional, Chan, Loi-Yuen, additional, Chen, Jennifer K., additional, Chen, Chen “Mary”, additional, Chiang, Nicole Yi Zhen, additional, Chiaravalloti, Anthony J., additional, Child, Fiona J., additional, Chu, Anthony C., additional, Clayton, Timothy H., additional, Cohen, Steven R., additional, Cooper, Elizabeth A., additional, Cooper, Susan M., additional, Collier, Nick, additional, Correnti, Christina M., additional, Coulson, Ian H., additional, Council, M. Laurin, additional, Cowper, Shawn E., additional, Craven, Nicholas M., additional, Creamer, Daniel, additional, Cruz, Ponciano D., additional, Cusack, Carrie Ann R., additional, Daunton, Adam, additional, Davis, Mark D.P., additional, Dawe, Robert S., additional, D’Cruz, David P., additional, de Berker, David, additional, DeHoratius, Danielle M., additional, Deng, Min, additional, Desai, Seemal R., additional, Devlin, Georgina, additional, DiGiovanna, John J., additional, Doctoroff, Alexander, additional, Dodiuk-Gad, Roni P., additional, Eichenfield, Dawn Z., additional, Eichenfield, Lawrence F., additional, Eisen, Drore, additional, Eke, Ure, additional, Elston, Dirk M., additional, Emanuel, Patrick O.M., additional, Enos, Clinton W., additional, Ensanyat, Shaheen H., additional, Falabella, Anna F., additional, Farberg, Aaron S., additional, Feigenbaum, Lawrence S., additional, Fernandez, Kristen Heins, additional, Fett, Nicole, additional, Finlay, Andrew Y., additional, Firoz, Bahar F., additional, Firoz, Elnaz F., additional, Fitzpatrick, James E., additional, Flischel, Amy E., additional, Foley, Kelly A., additional, Freedman, Derek, additional, Fremlin, Georgina A., additional, Fried, Richard, additional, Friedlander, Philip, additional, Friedman, Adam, additional, Forrestel, Amy K., additional, Fuchs, Brian S., additional, Gach, Joanna E., additional, Galan, Anjela, additional, Ganesh, Jaya, additional, Garg, Amit, additional, Geller, Lauren, additional, Gelmetti, Carlo M., additional, Ghazi, Elizabeth, additional, Ghunawat, Sneha, additional, Goldberg, Leonard H., additional, Goodfield, Mark J.D., additional, Gordon, Marsha L., additional, Gowda, Asha, additional, Grabell, Daniel A., additional, Grant, Matthew, additional, Grattan, Clive E.H., additional, Greaves, Malcolm W., additional, Green, Justin J., additional, Griffiths, Christopher E.M., additional, Gropper, Charles A., additional, Grossberg, Anna L., additional, Gupta, Aditya K., additional, Hadi, Ali S., additional, Hadi, Suhail M., additional, Hagans, Iris A., additional, Hairston, Bethany R., additional, Halpern, Analisa Vincent, additional, Halverstam, Caroline, additional, Harper, Natasha, additional, Harries, Matthew J., additional, Harris, John, additional, Harrison, Shannon, additional, Hatch, Michael M., additional, Heagerty, Adrian H.M., additional, Hebert, Adelaide A., additional, Helms, Stephen E., additional, Hexsel, Camile L., additional, Hexsel, Doris M., additional, Heymann, Warren R., additional, Higgins, Elisabeth M., additional, Higgins, Claire L., additional, High, Whitney A., additional, Hönigsmann, Herbert, additional, Horenstein, Marcelo G., additional, Hruza, George J., additional, Hui, Andrea, additional, Huo, Ran, additional, Ibbotson, Sally H., additional, Ibrahim, Sherrif F., additional, Ilchyshyn, Andrew, additional, Ismail, Dina, additional, Jablonska, Stefania, additional, Jacobe, Heidi T., additional, James, William D., additional, Javed, Aysha, additional, Jemec, Gregor B.E., additional, Johnston, Graham A., additional, Jones, Stephen K., additional, Junkins-Hopkins, Jacqueline M., additional, Kaffenberger, Jessica, additional, Kane, Kelly R., additional, Kanelleas, Antonios, additional, Karadağ, Ayşe Serap, additional, Karas, Laura, additional, Katugampola, Ruwani P., additional, Katz, Bruce E., additional, Kellen, Roselyn, additional, Khan, Murtaza, additional, Khorasani, Hooman, additional, Kim, Ellen J., additional, Kim, Hee J., additional, Kirby, Brian, additional, Kirby, Joslyn S., additional, Klein, Rachel S., additional, Kleydman, Kate, additional, Koch, Dimitra, additional, Kohorst, John J., additional, Koo, John Y.M., additional, Kopp, Sandra A., additional, Korman, Neil J., additional, Kovarik, Carrie, additional, Kraemer, Kenneth H., additional, Krafchik, Bernice R., additional, Krishnamurthy, Karthik, additional, Kvernebo, Knut, additional, Lam, Charlene, additional, Lambert, Peter C., additional, Langtry, James A.A., additional, Larian, Amir A., additional, Larocca, Cecilia A., additional, Lawlor, E. Frances, additional, Lawrence, Clifford M., additional, Lebwohl, Mark G., additional, Lebwohl, Oscar, additional, Lehman, Julia S., additional, Leslie, Tabi A., additional, Lessin, Stuart R., additional, Levitt, Jacob O., additional, Lewis, Fiona M., additional, Liaqat, Maryam, additional, Liu, Kristina J., additional, Loosemore, Michael P., additional, Luger, Thomas A., additional, Lupi, Omar, additional, Lushniak, Boris D., additional, Lyon, Calum C., additional, Maderal, Andrea D., additional, Mahmoud, Bassel H., additional, Majewski, Slawomir, additional, Mallett, Richard B., additional, Manders, Steven M., additional, Mann, Ranon, additional, Mansouri, Yasaman, additional, Margolis, David J., additional, Markowitz, Orit, additional, Marsland, Alexander, additional, Martin-Clavijo, Agustin, additional, Martinez, Daniela, additional, Matiz, Catalina, additional, Maurer, Marcus, additional, McKerrow, Kevin, additional, Meah, Nekma, additional, Micali, Giuseppe, additional, Micheletti, Robert G., additional, Millard, Leslie G., additional, Miller, James E., additional, Wong Millsop, Jillian W., additional, Mimouni, Daniel, additional, Mirowski, Ginat W., additional, Mirza, Sultan A., additional, Molin, Sonja, additional, Morales-Burgos, Adisbeth, additional, Morison, Warwick L., additional, Mørk, Cato, additional, Morton, Colin A., additional, Motley, Richard J., additional, Mowbray, Megan, additional, Muldoon, Eavan G., additional, Muncaster, Anna E., additional, Murakawa, George J., additional, Murase, Jenny E., additional, Murdoch, Michele E., additional, Nabatian, Adam S., additional, Nakamura, Mio, additional, Nalluri, Rajani, additional, Nawas, Zeena Y., additional, Needham, Glen R., additional, Newell, Glenn C., additional, Newton-Bishop, Julia, additional, Nguyen, Adam V., additional, Nixon, Rosemary L., additional, O’Brien, Jack C., additional, Ogden, Stephanie, additional, Olbricht, Suzanne M., additional, O’Shea, Sally Jane, additional, Owen, Cindy E., additional, Pan, Michael, additional, Pappas-Taffer, Lisa, additional, Parish, Jennifer L., additional, Parish, Lawrence Charles, additional, Payette, Michael, additional, Peck, Gary L., additional, Pena, Sandra, additional, Peranteau, Jarad, additional, Pereira, Frederick A., additional, Perkins, William, additional, Perlis, Clifford S., additional, Phelps, Robert G., additional, Phillips, Tania J., additional, Poh-Fitzpatrick, Maureen B., additional, Pomeranz, Miriam Keltz, additional, Pop, Samantha R., additional, Porcu, Pierluigi, additional, Powell, James B., additional, Prok, Lori D., additional, Pyle, Tia M., additional, Qazaz, Surod, additional, Rajkomar, Vikram, additional, Rashid, Rabia S., additional, Rashighi, Mehdi, additional, Ratnavel, Ravi, additional, Regula, Christie G., additional, Renzi, Michael, additional, Revuz, Jean, additional, Reynolds, Rachel V., additional, Richard, Elisabeth, additional, Richard, Gabriele, additional, Rigel, Darrell S., additional, Robles, Wanda Sonia, additional, Rogge, Megan, additional, Rook, Alain H., additional, Manning, Jamie R., additional, Rosen, Ted, additional, Rosenbach, Misha, additional, Rosenfeld, David, additional, Rowland Payne, Christopher, additional, Rubin, Adam I., additional, Rubin, Courtney, additional, Rustin, Malcolm H.A., additional, Ruzicka, Thomas, additional, Samimi, Sara, additional, Schachner, Lawrence A., additional, Scheinfeld, Noah, additional, Schlosser, Bethanee J., additional, Schnur, Rhonda E., additional, Schwartz, Robert A., additional, Scorer, Matthew J., additional, Selkin, Bryan A., additional, Seymour, Jamie, additional, Shaver, Christine M., additional, Shea, Christopher R., additional, Shear, Neil H., additional, Shim, Tang Ngee, additional, Shimizu, Hiroshi, additional, Siegel, Julia, additional, Singer, Elisha, additional, Skelsey, Maral Kibarian, additional, Sladden, Chris, additional, Sladden, Michael, additional, Smith, Janellen, additional, Smucker, Joanne E., additional, Somani, Najwa, additional, Sommer, Lacy L., additional, Sommerlad, Mary, additional, Soon, Christine, additional, Sopkovich, Jennifer A., additional, Soter, Nicholas A., additional, Spencer, James M., additional, Staughton, Richard C.D., additional, Sterling, Jane C., additional, Sunderkötter, Cord, additional, Taibjee, Saleem M., additional, Tamura, Deborah, additional, Tan, Eunice, additional, Tang, William Y-M., additional, Taylor, Lynsey, additional, Thiers, Bruce H., additional, Thomas, Lucy J., additional, Thornton, Cody R., additional, Tobin, Anne-Marie, additional, Torgerson, Rochelle R., additional, Tosti, Antonella, additional, Tsatsou, Fragkiski, additional, Tsuji-Abe, Yukiko, additional, Tucker, William F.G., additional, Tyring, Stephen K., additional, Udkoff, Jeremy, additional, Unger, Robin H., additional, Unger, Walter P., additional, Utz, Sarah, additional, Valbuena, Martha C., additional, van de Kerkhof, Peter, additional, Van Voorhees, Abby S., additional, Vangipuram, Ramya, additional, Veitch, David, additional, Venning, Vanessa, additional, Versteeg, Sarah G., additional, Viera, Martha, additional, Vittorio, Carmela C., additional, Vleugels, Ruth Ann, additional, Wali, Gorav N., additional, Wallengren, Joanna, additional, Wan, Joy, additional, Wanat, Karolyn A., additional, Weichert, Gabriele, additional, Weidmann, Anja K., additional, Weinberg, Jeffrey M., additional, Werth, Victoria P., additional, White, Lucile E., additional, Wiener, Adam H., additional, Wilkin, Jonathan K., additional, Wilkin, Nathaniel K., additional, Williams, Jason, additional, Wilson, Niall, additional, Wiss, Karen, additional, Witkowski, Joseph A., additional, Wiznia, Lauren E., additional, Wong, Henry K., additional, Wong, Junie Li Chun, additional, Wright, Andrew L., additional, Wriston, Cooper C., additional, Wu, Benedict C., additional, Wulkan, Adam, additional, Zaenglein, Andrea L., additional, Zaki, Irshad, additional, Zeichner, Joshua A., additional, Zhu, Tian Hao, additional, Zone, John J., additional, Zouboulis, Christos C., additional, and Zuberbeir, Torstein, additional

Published
2018
Full Text
View/download PDF

25. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project

Author

Midgette, Bria, primary, Strunk, Andrew, additional, Akilov, Oleg, additional, Alavi, Afsaneh, additional, Ardon, Christine, additional, Bechara, Falk G., additional, Cohen, Arnon D., additional, Cohen, Steven, additional, Daveluy, Steven, additional, del Marmol, Véronique, additional, Delage, Maïa, additional, Esmann, Solveig, additional, Fisher, Shani, additional, Giamarellos-Bourboulis, Evangelos J., additional, Glowaczewska, Amelia, additional, Goldfarb, Noah, additional, Brant, Elena Gonzalez, additional, Grimstad, Øystein, additional, Guilbault, Sandra, additional, Hamzavi, Iltefat, additional, Hughes, Rosalind, additional, Ingram, John R., additional, Jemec, Gregor B.E., additional, Ju, Qiang, additional, Kappe, Naomi, additional, Kirby, Brian, additional, Kirby, Joslyn S., additional, Lowes, Michelle A., additional, Matusiak, Lukasz, additional, Micha, Stella, additional, Micheletti, Robert, additional, Miller, Angela P., additional, Moseng, Dagfinn, additional, Naik, Haley, additional, Nassif, Aude, additional, Nikolakis, Georgios, additional, Paek, So Yeon, additional, Pascual, Jose Carlos, additional, Prens, Errol, additional, Resnik, Barry, additional, Riad, Hassan, additional, Sayed, Christopher, additional, Smith, Saxon D., additional, Soliman, Yssra, additional, Szepietowski, Jacek C., additional, Tan, Jerry, additional, Thorlacius, Linnea, additional, Tzellos, Thrasyvoulos, additional, van der Zee, Hessel H., additional, Villumsen, Bente, additional, Wang, Lanqi, additional, Zouboulis, Christos, additional, and Garg, Amit, additional

Published
2022
Full Text
View/download PDF

39. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa:results from the Global VOICE project

Author

Midgette, Bria, Strunk, Andrew, Akilov, Oleg, Alavi, Afsaneh, Ardon, Christine, Bechara, Falk G., Cohen, Arnon D., Cohen, Steven, Daveluy, Steven, del Marmol, Véronique, Delage, Maïa, Esmann, Solveig, Fisher, Shani, Giamarellos-Bourboulis, Evangelos J., Glowaczewska, Amelia, Goldfarb, Noah, Brant, Elena Gonzalez, Grimstad, Øystein, Guilbault, Sandra, Hamzavi, Iltefat, Hughes, Rosalind, Ingram, John R., Jemec, Gregor B.E., Ju, Qiang, Kappe, Naomi, Kirby, Brian, Kirby, Joslyn S., Lowes, Michelle A., Matusiak, Lukasz, Micha, Stella, Micheletti, Robert, Miller, Angela P., Moseng, Dagfinn, Naik, Haley, Nassif, Aude, Nikolakis, Georgios, Paek, So Yeon, Pascual, Jose Carlos, Prens, Errol, Resnik, Barry, Riad, Hassan, Sayed, Christopher, Smith, Saxon D., Soliman, Yssra, Szepietowski, Jacek C., Tan, Jerry, Thorlacius, Linnea, Tzellos, Thrasyvoulos, van der Zee, Hessel H., Villumsen, Bente, Wang, Lanqi, Zouboulis, Christos, Garg, Amit, Midgette, Bria, Strunk, Andrew, Akilov, Oleg, Alavi, Afsaneh, Ardon, Christine, Bechara, Falk G., Cohen, Arnon D., Cohen, Steven, Daveluy, Steven, del Marmol, Véronique, Delage, Maïa, Esmann, Solveig, Fisher, Shani, Giamarellos-Bourboulis, Evangelos J., Glowaczewska, Amelia, Goldfarb, Noah, Brant, Elena Gonzalez, Grimstad, Øystein, Guilbault, Sandra, Hamzavi, Iltefat, Hughes, Rosalind, Ingram, John R., Jemec, Gregor B.E., Ju, Qiang, Kappe, Naomi, Kirby, Brian, Kirby, Joslyn S., Lowes, Michelle A., Matusiak, Lukasz, Micha, Stella, Micheletti, Robert, Miller, Angela P., Moseng, Dagfinn, Naik, Haley, Nassif, Aude, Nikolakis, Georgios, Paek, So Yeon, Pascual, Jose Carlos, Prens, Errol, Resnik, Barry, Riad, Hassan, Sayed, Christopher, Smith, Saxon D., Soliman, Yssra, Szepietowski, Jacek C., Tan, Jerry, Thorlacius, Linnea, Tzellos, Thrasyvoulos, van der Zee, Hessel H., Villumsen, Bente, Wang, Lanqi, Zouboulis, Christos, and Garg, Amit

Abstract

Background: Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives: To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. Methods: Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients’ self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from ‘very dissatisfied’ to ‘very satisfied’. Results: The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62–2·44, P < 0·001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2·36, 95% CI 1·74–3·19, P < 0·001] relative to treatment with nonbiologic systemic medications. Factors associated with lower treatment satisfaction included smoking (OR 0·78, 95% CI 0·62–0·99; active vs. never), depression (OR 0·69, 95% CI 0·54–0·87), increasing number of comorbidities (OR 0·88 per comorbidity, 95% CI 0·81–0·96) and increasing flare frequency. Conclusions: There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication. Factors that appear to

Published
2022

41. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.

Author

Schell, Stephanie L, Cong, Zhaoyuan, Sennett, Mackenzie L, Gettle, Samantha L, Longenecker, Amy L, Goldberg, Stephanie R, Kirby, Joslyn S, Helm, Matthew F, and Nelson, Amanda M

Subjects
KERATINOCYTES, KILLER cells, HIDRADENITIS suppurativa, EPIDERMIS, POLYMERASE chain reaction, INFLAMMATION
Abstract

Background Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease characterized by painful nodules, drainage and scarring in skin folds. Injectable adalimumab is the only drug approved by the US Food and Drug Administration for the treatment of HS. Although systemic Janus kinase (JAK) inhibitors show promise, serious side-effects have been reported. There are no highly effective topical treatments for HS; furthermore, the contribution of epidermal keratinocytes to the intense inflammation has largely been unexplored. Objectives We investigated the role of keratinocytes and epidermal immune cells in HS inflammation at all Hurley stages of disease severity. We aimed to determine whether ruxolitinib can mitigate inflammation from keratinocytes and to develop a better understanding of how topical therapeutics might benefit patients with HS. Methods We used skin samples from 87 patients with HS (Hurley stages I–III) and 39 healthy controls to compare keratinocyte- and immune cell-driven epidermal inflammation, in addition to the response of lesional HS keratinocytes to treatment with interferon (IFN)-γ and ruxolitinib. We used haematoxylin and eosin staining, immunohistochemistry, immunoblotting and quantitative reverse-transcription polymerase chain reaction assessments in whole skin, isolated epidermis, and cultured keratinocytes from healthy controls and both nonlesional and lesional HS skin to identify and define epidermal and keratinocyte-mediated inflammation in HS and how this may be targeted by therapeutics. Results HS lesional keratinocytes autonomously secreted high levels of chemokines, such as CCL2, CCL3 and CXCL3, which recruited neutrophils, CD8 T cells, and natural killer cells to the epidermis. Keratinocytes were the dominant source of tumour necrosis factor-α and interleukin (IL)-6 in HS lesions with little to no contribution from underlying dermal immune cells. In the presence of IFN-γ, which is dependent on immune cell infiltrate in vivo , keratinocytes expressed increased levels of additional cytokines including IL-1β, IL-12, IL-23 and IL-36γ. The JAK inhibitor ruxolitinib mitigated the expression of inflammatory cytokines and chemokines in HS lesional keratinocytes, thus providing a rationale for future study as a topical treatment for HS. Conclusions This study demonstrates that keratinocytes actively recruit immune cells to HS epidermis and interactions between these cells drive a broad inflammatory profile in HS epidermis. Targeting epidermal inflammation in HS with novel topical formulations may be highly efficacious with reduced systemic side-effects. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results